Obermatt
See Similar Stocks →

Nkarta

NSQ:NKTX · US65487U1088
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings12
Price/Book69
Dividend Yield—
Revenue Growth—
Profit Growth67
Capital Growth71
TSR 52w46
Leverage25
Liquidity47
Refinancing43
Combined—
Analyst Opinions64
Pro Holdings73
Opinion Changes50
Market Pulse73

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees124
Websitenkartatx.com
ISINUS65487U1088
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesRheumatologyNeurologyImmunologyStem Cell TherapyHematologyOncologyBiotechnologyHealth Care

Description

Nkarta, Inc. operates as a clinical-stage biopharmaceutical company. The company is pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company’s lead pipeline program is NKX019, a chimeric anti…

Similar Stocks

The companies this stock is ranked against.

Compare Nkarta with its peers
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sana Biotechnology
NSQ:SANA
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galectin Therapeutics
NAQ:GALT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →